Sign in

    Alexandra Hammond

    Senior Research Analyst and Head of Therapeutics Research at Wolfe Research

    Alexandria Hammond is a Senior Research Analyst and Head of Therapeutics Research at Wolfe Research, specializing in the coverage of global pharmaceutical and large cap biotechnology companies. She has led coverage on major names such as Amgen and Gilead Sciences, with a track record that includes her prior role at Bank of America where she was part of a top-ranked Institutional Investor team in Major Pharma and Large Cap Biotech. Hammond began her career after earning a BS in Cell and Molecular Biology from Binghamton University and a PhD in Microbiology from NYU School of Medicine, subsequently joining BofA Securities and moving to Wolfe Research in 2024 to launch their therapeutics coverage. She holds advanced scientific credentials and is recognized as a rising star in healthcare equity research.

    Alexandra Hammond's questions to BRISTOL MYERS SQUIBB (BMY) leadership

    Alexandra Hammond's questions to BRISTOL MYERS SQUIBB (BMY) leadership • Q4 2024

    Question

    Alexandra Hammond of Wolfe Research asked management to highlight the key pipeline assets they believe will drive revenue in the latter half of the decade, referring to them as their "favorite child or two."

    Answer

    CEO Christopher Boerner declined to pick a favorite, citing a "wealth of opportunity." He highlighted a first wave of major assets including Cobenfy, multiple CELMoD programs (iberdomide, mezigdomide, gocotomide), Milvexian, and LPA1. He also mentioned a next wave of assets, emphasizing the numerous potential catalysts expected over the next 24 months.

    Ask Fintool Equity Research AI